<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202014000100014</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Betabloqueantes e inhibidores del sistema renina-angiotensina-aldosterona en el síndrome coronario agudo]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jubany]]></surname>
<given-names><![CDATA[Luciana]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kuster]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Instituto Nacional de Cirugía Cardíaca  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Servicio Médico Integral Unidad Cardiológica ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2014</year>
</pub-date>
<volume>29</volume>
<numero>1</numero>
<fpage>100</fpage>
<lpage>109</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202014000100014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202014000100014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202014000100014&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Los betabloqueantes y los inhibidores de la enzima convertidora de angiotensina / antagonistas de los receptores de angiotensina II (I-ECA/ARA II) son medicamentos esenciales en el manejo del síndrome coronario agudo (SCA) con un efecto beneficioso en la sobrevida, aditivo al obtenido con otros fármacos, como aspirina y estatinas, reduciendo la morbi-mortalidad temprana y tardía en pacientes revascularizados o no. Los pacientes pos IAM con fracción de eyección del ventrículo izquierdo (FEVI) < 40% e insuficiencia cardíaca o diabetes, se pueden beneficiar del tratamiento con antagonistas de los receptores mineralocorticoides si se aplican en forma temprana.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[SISTEMA RENINA-ANGIOTENSINA - efectos de drogas]]></kwd>
<kwd lng="es"><![CDATA[SINDROME CORONARIO AGUDO]]></kwd>
<kwd lng="es"><![CDATA[ANTAGONISTAS ADRENÉRGICOS BETA]]></kwd>
<kwd lng="es"><![CDATA[INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA]]></kwd>
<kwd lng="en"><![CDATA[RENIN-ANGIOTENSIN SYSTEM - drug effects]]></kwd>
<kwd lng="en"><![CDATA[ACUTE CORONARY SYNDROME]]></kwd>
<kwd lng="en"><![CDATA[ADRENERGIC BETA-ANTAGONISTS]]></kwd>
<kwd lng="en"><![CDATA[ANGIOTENSIN-CONVERTING ENZYME INHIBITORS]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[        <basefont size="3"> <multicol gutter="18" cols="2"></multicol>     <p align="left"><font face="Verdana" size="2"><b>Art&iacute;culo de revisi&oacute;n&nbsp;</b></font></p>       <b>       <font face="Verdana" size="4"> Betabloqueantes e inhibidores del sistema renina-angiotensina-aldosterona en el s&iacute;ndrome coronario agudo&nbsp; </font> </b>         <p align="left"><font face="Verdana" size="2"> Dres. Luciana Jubany<a name="-a"></a></font><font color="#d62437" face="Candara"><a href="#a"><font face="Verdana" size="2"><sup>1</sup></font></a></font><font face="Verdana" size="2">, Fernando Kuster</font><sup><font face="Verdana" size="2"><a name="-b"></a></font><font color="#d62437" face="Verdana" size="2"><a href="#b">2</a></font></sup><font face="Verdana" size="2">&nbsp; </font><font face="Verdana"><font size="2">    <br>       </font>       <basefont size="3"> </font> </p>           <p align="left"><font face="Verdana" size="2"><a name="a"></a> </font> <font color="#1f1a17" face="Verdana" size="2"> <a href="#-a">1</a></font><font face="Verdana" size="2">. M&eacute;dico Residente de Cardiolog&iacute;a. Instituto Nacional de Cirug&iacute;a Card&iacute;aca   y Servicio M&eacute;dico Integral (INCC- SMI).    <br>      <a name="b"></a> </font><font color="#1f1a17" face="Verdana" size="2"> <a href="#-b">2</a></font><font face="Verdana" size="2">. M&eacute;dico Cardi&oacute;logo. Coordinador   Unidad Cardiol&oacute;gica del Servicio M&eacute;dico Integral (SMI).    <br>          <b>Correspondencia:</b> Dr. Fernando Kuster. Correo electr&oacute;nico </font> <font color="#1f1a17" face="Verdana" size="2"> <a href="mailto:fkuster@netgate.com.uy">fkuster@netgate.com.uy</a></font><font face="Verdana" size="2">&nbsp;</font></p>      <p align="left">&nbsp;</p>           <p align="left"><font face="Verdana" size="2"> <b>Resumen&nbsp;</b> </font></p>           <p align="left"><font face="Verdana" size="2"> Los betabloqueantes y los inhibidores de la enzima convertidora de angiotensina  / antagonistas de los receptores de angiotensina II (I-ECA/ARA II) son  medicamentos esenciales en el manejo del s&iacute;ndrome coronario agudo (SCA)  con un efecto beneficioso en la sobrevida, aditivo al obtenido con otros  f&aacute;rmacos, como aspirina y estatinas, reduciendo la morbi-mortalidad temprana  y tard&iacute;a en pacientes revascularizados o no. Los pacientes pos IAM con  fracci&oacute;n de eyecci&oacute;n del ventr&iacute;culo izquierdo (FEVI) &lt; 40% e insuficiencia  card&iacute;aca o diabetes, se pueden beneficiar del tratamiento con antagonistas  de los receptores mineralocorticoides si se aplican en forma temprana.&nbsp; </font></p>           ]]></body>
<body><![CDATA[<p align="left"> <font face="Verdana" size="2"><b>Palabras clave:    <br>       &nbsp;&nbsp;&nbsp;&nbsp;</b></font><font face="Verdana" size="1"><!-- big -->SISTEMA RENINA-ANGIOTENSINA<!-- /big --></font><font face="Verdana" size="2"> - efectos de drogas    <br>       &nbsp;&nbsp;&nbsp;&nbsp;SINDROME  CORONARIO AGUDO    <br>       &nbsp;&nbsp;&nbsp;&nbsp;ANTAGONISTAS ADREN&Eacute;RGICOS BETA    <br>       &nbsp;&nbsp;&nbsp;&nbsp;INHIBIDORES DE LA ENZIMA CONVERTIDORA  DE ANGIOTENSINA&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2">    <br>         <b>Keywords:</b>    <br>       &nbsp;&nbsp;&nbsp;&nbsp;RENIN-ANGIOTENSIN SYSTEM - drug effects    <br>       &nbsp;&nbsp;&nbsp;&nbsp;ACUTE CORONARY SYNDROME    <br>       &nbsp;&nbsp;&nbsp;&nbsp;ADRENERGIC  BETA-ANTAGONISTS    ]]></body>
<body><![CDATA[<br>       &nbsp;&nbsp;&nbsp;&nbsp;ANGIOTENSIN-CONVERTING ENZYME INHIBITORS&nbsp;         </font></p>           <p align="left"><font face="Verdana" size="2">     <br>       </font></p>           <p align="left"><font face="Verdana" size="2"> <b>Introducci&oacute;n&nbsp;</b> </font></p>           <p align="left"><font face="Verdana" size="2"> La enfermedad coronaria es una enfermedad cr&oacute;nica, una de cuyas formas  de presentaci&oacute;n es el SCA con y sin elevaci&oacute;n del segmento ST (SCAcST,  SCAsST). Todo paciente que haya sufrido un SCA debe recibir tratamiento  de prevenci&oacute;n secundaria por el alto riesgo de sufrir nuevos eventos y  muerte prematura.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Existen diferentes intervenciones que han demostrado mejorar el pron&oacute;stico  y el inicio de las mismas durante la internaci&oacute;n aumenta la probabilidad  de su utilizaci&oacute;n posterior.&nbsp; </font></p>       <font face="Verdana" size="2"> En esta revisi&oacute;n nos vamos a referir al uso de betabloqueantes (BB) y los  inhibidores del sistema renina-angiotensina-aldosterona (SRAA).&nbsp;&nbsp;    <br>  </font>             <p align="left"><font face="Verdana" size="2"> <b>Betabloqueantes&nbsp;</b></font></p>         <p align="left"><font face="Verdana" size="2"> Sir James W. Black, m&eacute;dico y farmac&oacute;logo escoc&eacute;s, fue quien desarroll&oacute;  el primer BB, llamado pronethalol, que mediante el bloqueo de las catecolaminas  disminu&iacute;a la frecuencia y la intensidad de los latidos card&iacute;acos. En la  d&eacute;cada de 1960, desarroll&oacute; el propranolol, primer BB para uso cl&iacute;nico,  y fueron sus investigaciones en este campo las que lo llevaron a ganar  el premio Nobel de Medicina en 1988. En ese momento afirm&oacute;: &ldquo;&hellip;es el mayor  descubrimiento farmacol&oacute;gico para tratar las enfermedades card&iacute;acas desde  la digital hace 200 a&ntilde;os...&rdquo;</font><sup><font face="Verdana" size="2">(<a name="-1"></a></font><font color="#1f1a17" face="Verdana" size="2"><a href="#1">1</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Inicialmente, el cuerpo m&eacute;dico los recibi&oacute; con reservas, debido a su acci&oacute;n  depresora de la funci&oacute;n contr&aacute;ctil, aduciendo que podr&iacute;an tener efectos  delet&eacute;reos en las enfermedades card&iacute;acas. Fue reci&eacute;n en 1974 cuando por  primera vez se publica su uso, por parte de Waagstein, en una paciente  que cursaba infarto con falla card&iacute;aca y taquicardia sinusal</font><sup><font face="Verdana" size="2"><a name="-2"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#2">2</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>         <multicol gutter="18" cols="2"></multicol>     ]]></body>
<body><![CDATA[<p align="left"><font face="Verdana" size="2"> En un estudio posterior se comprueba su utilidad en la mejor&iacute;a de los pacientes  con insuficiencia card&iacute;aca por miocardiopat&iacute;a dilatada sin lesiones coronarias,  por lo que su beneficio no solamente se vincul&oacute; a la isquemia mioc&aacute;rdica<a name="-3"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#3">3</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Actualmente los BB son esenciales en el manejo del SCA. Las gu&iacute;as de tratamiento  del SCAcST y del SCAsST, tanto del Colegio Americano de Cardiolog&iacute;a/Asociaci&oacute;n  Americana del Coraz&oacute;n (ACCF/ AHA), como de la Sociedad Espa&ntilde;ola de Cardiolog&iacute;a  (SEC), los indican en todos los pacientes que no presentan contraindicaciones  para su uso, siendo una recomendaci&oacute;n clase I, nivel de evidencia A, lo  que demuestra que existe acuerdo general a partir de datos provenientes  de m&uacute;ltiples ensayos cl&iacute;nicos aleatorizados y metaan&aacute;lisis<a name="-4"></a><a name="-5"></a><a name="-6"></a><a name="-7"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#4">4-7</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Los efectos potencialmente beneficiosos de los BB en los SCA son:&nbsp; </font></p>       <ul>             <li><font face="Verdana" size="2"> Descenso de la demanda de ox&iacute;geno por reducci&oacute;n de la frecuencia card&iacute;aca,  la presi&oacute;n arterial y la contractilidad, con la consiguiente disminuci&oacute;n  de la isquemia mioc&aacute;rdica<a name="-8"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#8">8</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></li>             <li><font face="Verdana" size="2"> Descenso del riesgo de fibrilaci&oacute;n ventricular (FV) por aumento del umbral  fibrilatorio, evidenciado en estudios cl&iacute;nicos por la reducci&oacute;n del riesgo  relativo de muerte s&uacute;bita entre 30% y 40%<a name="-9"></a><a name="-10"></a><a name="-11"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#9">9-11</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></li>             <li><font face="Verdana" size="2"> Reducci&oacute;n del automatismo, con lo que aumenta el umbral de activaci&oacute;n celular  y se enlentece la conducci&oacute;n, produci&eacute;ndose bradicardia, lo que favorece  la perfusi&oacute;n mioc&aacute;rdica por prolongaci&oacute;n de la di&aacute;stole.&nbsp;     </font></li>             <li><font face="Verdana" size="2"> Reducci&oacute;n de la remodelaci&oacute;n ventricular y mejor&iacute;a de la funci&oacute;n del ventr&iacute;culo  izquierdo (VI), dependiendo del tama&ntilde;o ventricular y del tiempo de tratamiento<a name="-12"></a><a name="-13"></a><a name="-14"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#12">12-14</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></li>             <li><font face="Verdana" size="2"> Mejor&iacute;a de la funci&oacute;n diast&oacute;lica con reducci&oacute;n del patr&oacute;n restrictivo<a name="-15"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#15">15</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></li>             <li><font face="Verdana" size="2"> Enlentecimiento de la progresi&oacute;n de la aterosclerosis coronaria</font><sup><font face="Verdana" size="2"><a name="-16"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#16">16</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></li>           </ul>           ]]></body>
<body><![CDATA[<p align="left"><font face="Verdana" size="2"> <b>Eficacia.</b> Estudios cl&iacute;nicos en la era prefibrinol&iacute;tica demostraron una  reducci&oacute;n de la mortalidad entre 10% y 15% en los pacientes tratados con  BB</font><sup><font face="Verdana" size="2"><a name="-17"></a><a name="-18"></a><a name="-19"></a><a name="-20"></a><a name="-21"></a><a name="-22"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#17">17-22</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> En la era de la fibrin&oacute;lisis se demostr&oacute; una reducci&oacute;n de muerte a largo  plazo de 23%<a name="-23"></a><a name="-24"></a><a name="-25"></a><a name="-26"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#23">23-26</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">. Tambi&eacute;n tienen beneficio en los pacientes con infarto  agudo de miocardio (IAM) luego de la angioplastia primaria (ATC1&ordf;), asoci&aacute;ndose  con una reducci&oacute;n absoluta de riesgo de muerte de 4,4% a seis meses. Al  tratar a 23 pacientes, previene una muerte [n&uacute;mero necesario para tratar  (NNT)]. Los subgrupos de pacientes con enfermedad multivaso o con FEVI  &lt; 50% fueron los que mostraron una mayor reducci&oacute;n de eventos card&iacute;acos  mayores combinados (MACE) y mortalidad.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Sin embargo, estos mismos estudios demuestran que son infrautilizados,  a pesar que 80% a 90% de los pacientes con IAM son elegibles para este  tratamiento. Quienes no lo reciben en el hospital tampoco lo hacen en el  seguimiento ambulatorio. Dos grandes registros internacionales, Euro Heart  Survey of Acute Coronary Syndromes<a name="-32"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#32">32</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2"> y GRACE</font><sup><font face="Verdana" size="2"><a name="-33"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#33">33</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">, evaluaron el manejo  en 22.000 pacientes alrededor del mundo, incluida Am&eacute;rica del Sur, observ&aacute;ndose  que 72% a 76% de los pacientes al alta recibieron BB.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Se constata un mayor uso cuando el paciente estuvo internado en un servicio  de cardiolog&iacute;a que en un servicio de medicina</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#24">24</a></font><font face="Verdana" size="2">,</font><font color="#1f1a17" face="Verdana" size="2"><a href="#26">26</a></font><font face="Verdana" size="2">,</font><font color="#1f1a17" face="Verdana" size="2"><a href="#32">32</a></font><font face="Verdana" size="2">,</font><font color="#1f1a17" face="Verdana" size="2"><a href="#33">33</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Durante mucho tiempo en pacientes con diabetes se sobreestim&oacute; el riesgo  de su uso por la posibilidad de enmascarar los s&iacute;ntomas de hipoglucemia  o de empeorar el control metab&oacute;lico, pero el an&aacute;lisis de subgrupos de distintos  trabajos muestran igual o incluso mayor beneficio con el uso de los BB  en el infarto en estos pacientes.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Otro subgrupo de pacientes en quienes son infrautilizados y muestran beneficio  a corto y largo plazo son los portadores de enfermedad pulmonar obstructiva  cr&oacute;nica (EPOC)</font><sup><font face="Verdana" size="2"><a name="-27"></a><a name="-28"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#27">27</a></font><font face="Verdana" size="2">,</font><font color="#1f1a17" face="Verdana" size="2"><a href="#28">28</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> El efecto sobre la mortalidad se debe a la disminuci&oacute;n de muerte s&uacute;bita,  quedando demostrada su reducci&oacute;n de 5% a 3,3% en una revisi&oacute;n de 13 trials<a name="-29"></a><a name="-30"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#29">29-30</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> En el estudio CAPRICORN se objetiv&oacute; el beneficio de los BB en pacientes  con disfunci&oacute;n del VI con FEVI &lt; 40% luego del IAM, tratados con I-ECA,  a los que se les administraba placebo o carvedilol. Se produjo una reducci&oacute;n  significativa de la mortalidad por todas las causas y del IAM no fatal  entre los tratados con BB. No se redujo el punto final combinado de mortalidad  por todas las causas y hospitalizaci&oacute;n por causas cardiovasculares</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#28">28</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> <b>Selecci&oacute;n de pacientes.</b> Los BB son de aplicaci&oacute;n universal despu&eacute;s de un  IAM.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> <b>Contraindicaciones.</b> Las mayores son: broncoespasmo activo, bradicardia  severa, bloqueo auriculoventricular mayor a primer grado, edema pulmonar,  hipotensi&oacute;n arterial con o sin shock. Los IAM precipitados por el consumo  de coca&iacute;na no deben recibir BB, ya que pueden agravar el espasmo coronario.&nbsp; </font></p>           ]]></body>
<body><![CDATA[<p align="left"><font face="Verdana" size="2"> <b>Modo de administraci&oacute;n.</b> Pueden ser administrados en forma temprana entre  cuatro a seis horas pos IAM o en forma m&aacute;s tard&iacute;a.&nbsp; </font></p>            <p>  <multicol gutter="18" cols="2"></multicol> </p>          <p align="left"><font face="Verdana" size="2"> <b>Administraci&oacute;n precoz.</b> El estudio COMMIT/ CCS2</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#27">27</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">, realizado en 45.852  pacientes de los cuales el 93% ten&iacute;a elevaci&oacute;n del segmento ST o bloqueo  de rama, no evidenci&oacute; diferencias en la mortalidad al administrar metoprolol  intravenoso versus placebo. S&iacute; se verific&oacute; aumento de la mortalidad con  BB por incremento de la incidencia de shock cuando exist&iacute;a compromiso hemodin&aacute;mico.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Al segundo d&iacute;a pos IAM se observ&oacute; reducci&oacute;n de la FV y de la tasa de reinfarto  en los pacientes con BB.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> En el estudio retrospectivo GUSTO-I</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#24">24</a></font><font face="Verdana" size="2">) </font> </sup> <font face="Verdana" size="2">, la administraci&oacute;n de BB por v&iacute;a  intravenosa en el 44% de los pacientes tambi&eacute;n se asoci&oacute; a un efecto adverso  con mayor incidencia de insuficiencia card&iacute;aca.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Actualmente los BB intravenosos se restringen a los pacientes con taquicardia  o hipertensi&oacute;n arterial en una situaci&oacute;n hiperdin&aacute;mica e hiperadren&eacute;rgica  desproporcionada para el tama&ntilde;o del IAM.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Las gu&iacute;as recomiendan no administrar BB en pacientes con riesgo de shock  cardiog&eacute;nico y optar por la v&iacute;a oral, luego de la estabilidad hemodin&aacute;mica,  o revalorar la situaci&oacute;n de la persistencia o no de las contraindicaciones  tempranas para poder iniciarlos.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> En el estudio TIMI-2, en los pacientes que recibieron fibrinol&iacute;ticos, el  uso precoz de BB redujo el sangrado intracraneal<a name="-31"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#31">31</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">, pero esto no fue  confirmado por otros estudios cl&iacute;nicos.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> <b>Administraci&oacute;n tard&iacute;a.</b> Estudios controlados en pacientes con IAM en quienes  se efect&uacute;a terapia de revascularizaci&oacute;n por fibrin&oacute;lisis o por ATC1&ordf;, no  han demostrado diferencias en el beneficio entre la administraci&oacute;n inmediata  y la tard&iacute;a.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> En general se prefiere la administraci&oacute;n temprana ya que ha evidenciado  menor recurrencia de &aacute;ngor, menor tasa de reinfarto a seis d&iacute;as y menor  mortalidad.&nbsp; </font></p>           ]]></body>
<body><![CDATA[<p align="left"><font face="Verdana" size="2"> <b>Elecci&oacute;n del f&aacute;rmaco.</b> El efecto beneficioso de disminuci&oacute;n de la mortalidad  es un efecto de clase de los BB; se prefieren sin actividad simpaticomim&eacute;tica  intr&iacute;nseca.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Se recomienda el uso de los BB cardioselectivos en casi todos los pacientes  con SCA, como atenolol y metoprolol succinato, y cuando se asocia con insuficiencia  card&iacute;aca est&aacute;n indicados carvedilol, metoprolol succinato o bisoprolol.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> <b>Frecuencia card&iacute;aca objetivo.</b> La hip&oacute;tesis de una relaci&oacute;n inversa entre  la frecuencia card&iacute;aca y la reducci&oacute;n de la mortalidad despu&eacute;s de un IAM  fue sugerida en la d&eacute;cada de 1980 y confirmada en un metaan&aacute;lisis de regresi&oacute;n  de 17 estudios cl&iacute;nicos (14 trials con BB y tres con calcio- antagonistas)  en 31.000 pacientes, demostrando una reducci&oacute;n estad&iacute;sticamente significativa  de todas las muertes, muertes card&iacute;acas e infarto no fatal cuando la frecuencia  card&iacute;aca basal desciende entre 5 y 15 latidos por minuto, aunque no se  ha establecido a&uacute;n el valor &oacute;ptimo<a name="-34"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#34">34</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> <b>Dosis a usar. </b>En la iniciaci&oacute;n de la terapia oral se debe ir incrementando  la dosis de acuerdo a la respuesta obtenida, ya que no existe un esquema  r&iacute;gido porque el SCA determina una respuesta simp&aacute;tica variable. Las limitaciones  a las dosis plenas son la bradicardia y la hipotensi&oacute;n arterial. La dosis  objetiva ser&iacute;a aquella que reduce la frecuencia card&iacute;aca a &pound; 70 cpm mientras  se mantiene la presi&oacute;n arterial sist&oacute;lica &gt; 90 mm Hg.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> <b>Duraci&oacute;n del tratamiento. </b>La duraci&oacute;n &oacute;ptima del tratamiento no est&aacute; establecida.  Un metaan&aacute;lisis de 1999</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#24">24</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2"> demostr&oacute; una reducci&oacute;n de riesgo de muerte  de 23% en un seguimiento de 1,4 a&ntilde;os. Una evaluaci&oacute;n contempor&aacute;nea en el  potencial beneficio a largo plazo se realiz&oacute; en 2012, con un estudio observacional  sobre 14.000 pacientes, el registro internacional REACH. Cuando el objetivo  final fue el evento combinado de muerte CV, IAM no fatal y stroke no fatal,  luego de 44 meses no hubo diferencias significativas entre los pacientes  tratados o no (16,9% versus 18,6%; IC 0,79-1,03). Se comprob&oacute; una peque&ntilde;a  diferencia en los eventos a favor del grupo BB que en los no BB luego de  dos a&ntilde;os.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Se evalu&oacute; la evoluci&oacute;n de pacientes con IAM tratados con ATC1&ordf; durante  un seguimiento de 1.430 d&iacute;as, las tasas de mortalidad no fueron diferentes  entre los tratados con o sin BB (5,5% versus 6,2%); sin embargo, el an&aacute;lisis  por subgrupos mostr&oacute; una menor mortalidad en los pacientes con BB que eran  de alto riesgo y con insuficiencia card&iacute;aca.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> La evidencia apoya el uso de BB en los pacientes con IAM por tres a&ntilde;os  y en forma prolongada en aquellos pacientes con elementos de riesgo durante  el IAM como shock, insuficiencia card&iacute;aca y enfermedad renal.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> En los pacientes que refieren efectos colaterales inaceptables por BB,  durante su tratamiento se debe usar el protocolo de retiro de estos en  forma progresiva.&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> <b>En suma&nbsp;</b> </font></p>           <p align="left"><font face="Verdana" size="2"> La mayor&iacute;a de pacientes con SCAcST y SCAsST, incluso revascularizados,  se benefician con los BB, reduciendo sus complicaciones y mejorando su  sobrevida a largo plazo</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#4">4-7</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>           ]]></body>
<body><![CDATA[<p align="left"><font face="Verdana" size="2"> En ausencia de contraindicaciones se inician dentro de las primeras 24  horas en todos los pacientes con IAM (Indicaci&oacute;n 1 A).&nbsp; </font></p>         <multicol gutter="18" cols="2"></multicol>     <p align="left"><font face="Verdana" size="2"> Se sugiere el uso intravenoso cuando los pacientes se presentan hipertensos  (Indicaci&oacute;n 2 B).&nbsp; </font></p>           <p align="left"><font face="Verdana" size="2"> Quienes no los reciben en las primeras 24 horas por contraindicaci&oacute;n temprana,  deber&iacute;an ser reevaluados para decidir si son candidatos a su uso posterior.  En ausencia de contraindicaciones, se recomienda el uso continuo por v&iacute;a  oral por un m&iacute;nimo de dos a&ntilde;os en todos los pacientes que tuvieron un IAM  (Indicaci&oacute;n 1 B).&nbsp; </font></p>       <font face="Verdana" size="2"> Los pacientes con indicaci&oacute;n de tratamiento indefinido son aquellos con  disfunci&oacute;n sist&oacute;lica del VI (Indicaci&oacute;n 2 C).     <br>          <br>       </font>           <p align="left"><font face="Verdana" size="2"> <b>Inhibici&oacute;n del sistema renina-angiotensina-aldosterona en el SCA&nbsp;</b></font></p>    <font face="Verdana" size="2">       <br>    Durante las primeras 24 horas de un infarto existe un aumento en la activaci&oacute;n  del SRAA que genera diversos efectos adversos a nivel cardiovascular, por  lo que el bloqueo de este sistema ha sido foco de una importante investigaci&oacute;n  cardiovascular en los &uacute;ltimos 30 a&ntilde;os.&nbsp;     <br>          <br>       </font>           <p align="left"><font face="Verdana" size="2"> <b>Inhibici&oacute;n de la enzima conversora&nbsp;</b></font></p>        ]]></body>
<body><![CDATA[<p style="text-align: left;"><font face="Verdana" size="2"> El mayor beneficio de estos f&aacute;rmacos en la sobrevida de los pacientes pos  IAM se ha vinculado a su efecto en la reducci&oacute;n del remodelado ventricular  que ocurre en d&iacute;as a semanas siguientes al evento agudo. Est&aacute; directamente  relacionado con el pron&oacute;stico: a mayor remodelado y dilataci&oacute;n ventricular,  mayor es el riesgo de insuficiencia card&iacute;aca y muerte s&uacute;bita. El efecto  de los I-ECA en el remodelado ventricular es un beneficio cr&oacute;nico, pero  en agudo reduce la injuria mioc&aacute;rdica, la degradaci&oacute;n de las reservas de  fosfatos de alta energ&iacute;a y el deterioro de la respuesta arteriolar dependiente  del endotelio</font><sup><font face="Verdana" size="2"><a name="-35"></a><a name="-36"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#35">35-36</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> Otros mecanismos que se han relacionado con este beneficio son la reducci&oacute;n  de la muerte s&uacute;bita por mecanismo neurohumoral<a name="-38"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#38">38</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2"> y la preservaci&oacute;n del  precondicionamiento isqu&eacute;mico<a name="-37"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#37">37</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">. Si bien no tienen efecto antiarr&iacute;tmico,  el bloqueo del SRAA reduce el estr&eacute;s parietal tanto ventricular como auricular,  lo que interfiere en las corrientes i&oacute;nicas, desciende el tono simp&aacute;tico  y mejora la funci&oacute;n ventricular, lo que puede explicar el menor desarrollo  de arritmias auriculares y ventriculares.&nbsp; </font></p>          <p style="text-align: left;"><font face="Verdana" size="2"> <b>Efecto de los I-ECA sobre la funci&oacute;n ventricular y la mortalidad&nbsp;</b> </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> La mayor&iacute;a de los estudios aleatorizados se realiz&oacute; en pacientes con SCAcST,  en quienes se efectu&oacute; reperfusi&oacute;n mediante fibrinol&iacute;ticos o sin terapia  de reperfusi&oacute;n; pero en la ATC1&ordf; son m&aacute;s limitados los datos disponibles;  tambi&eacute;n en pacientes con SCAsST, pues existe un solo estudio</font><sup><font face="Verdana" size="2"><a name="-39"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#39">39</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> En la gran mayor&iacute;a de ellos se inici&oacute; tratamiento con distintos f&aacute;rmacos,  entre los que se incluyeron: captopril, enalapril, ramipril, lisinopril,  trandolapril o tofenopril, zofenopril entre 24 horas y 16 d&iacute;as pos IAM,  obteni&eacute;ndose una mejor&iacute;a en la FEVI desde el primer mes y mantenida hasta  el a&ntilde;o.&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> Ejemplos de estos estudios son el ISIS-4 (captopril)</font><sup><font face="Verdana" size="2"><a name="-40"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#40">40</a></font><font face="Verdana" size="2">) </font> </sup> <font face="Verdana" size="2">y el GISSI-3 (lisinopril)</font><sup><font face="Verdana" size="2"><a name="-41"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#41">41</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> Su utilizaci&oacute;n se asoci&oacute; a un mayor beneficio en la sobrevida de los pacientes  de alto riesgo, que incluye a pacientes con FEVI disminuida, falla card&iacute;aca  o infarto anterior extenso, comparados con los de bajo riesgo, con 50 vidas  salvadas cada 1.000 tratados versus 5 vidas salvadas cada 1.000 (NNT).  En los pacientes de alto riesgo el beneficio obtenido es mayor que el logrado  con otros tratamientos coadyuvantes y el beneficio de la reperfusi&oacute;n es  aditivo al uso de I-ECA.&nbsp; </font></p>          <p style="text-align: left;"><font face="Verdana" size="2"> <b>Beneficio en distintas poblaciones&nbsp;</b> </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> <i>&nbsp; En todos los pacientes&nbsp;</i> </font></p>        <div style="text-align: left;">   <font face="Verdana" size="2">El estudio ISIS-4 (The fourth International Study of Infarct Survival)</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#40">40</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">  enrol&oacute; a 58.050 pacientes con SCAcST que no presentaban hipotensi&oacute;n y se  asignaron en forma aleatoria a captopril 6,25 mg a 50 mg cada 12 horas  versus placebo, siendo iniciado en las primeras 24 horas y con una duraci&oacute;n  del tratamiento de un mes. Se observ&oacute; reducci&oacute;n de la mortalidad de 7%  a las cinco semanas del evento, que persisti&oacute; a los 12 meses; el beneficio  absoluto a los 12 meses fue de 0,5% (12% versus 12,5%). El beneficio fue  primariamente limitado a pacientes con IAM anterior, pero fue mayor en  los pacientes con falla card&iacute;aca o con antecedente de IAM previo.&nbsp;</font></div>        ]]></body>
<body><![CDATA[<p style="text-align: left;"><font face="Verdana" size="2"> El estudio GISSI-3 (Effects of lisinopril and transdermal glyceryl trinitrate  singly and together on 6-week mortality and ventricular function after  acute myocardial infarction)</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#41">41</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2"> incluy&oacute; a 19.000 pacientes randomizados  a lisinopril o placebo, comenzando en las primeras 24 horas con una dosis  inicial de 5 mg/d&iacute;a y continuando con 10 mg/d&iacute;a durante seis meses. Se  evidenci&oacute; una reducci&oacute;n relativa de 10% de la mortalidad y de la disfunci&oacute;n  del VI (OR 0,9).&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> El beneficio de lisinopril en la mortalidad en los pacientes con diabetes  a los seis meses fue estad&iacute;sticamente significativo: 8,7% versus 12,4%  (OR 0,68; IC 95%, 0,53-0,86), 37 vidas salvadas cada 1.000 tratados (NNT),  mayor que lo observado en los no diab&eacute;ticos en forma significativa (p &lt;  0,025). En los no diab&eacute;ticos solo redujo 5% la mortalidad, tres vidas salvadas  cada 1.000 tratados (NNT<a name="-42"></a>)</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#42">42</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>        <p style="text-align: left;">   <multicol gutter="18" cols="2"></multicol> </p>        <p style="text-align: left;"><font face="Verdana" size="2"> Ambos estudios demostraron que el beneficio temprano persiste a los cuatro  a&ntilde;os a pesar de la discontinuaci&oacute;n del f&aacute;rmaco.&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> <i>&nbsp; Pacientes con FEVI disminuida&nbsp;</i> </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> En el estudio SAVE (SurvivAl and Ventricular Enlargement<a name="-43"></a>)</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#43">43</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2"> se enrol&oacute;  a 2.231 pacientes con FEVI &pound; 40%, para recibir captopril en dosis progresivas  de hasta 50 mg dos veces por d&iacute;a entre los tres y los 16 d&iacute;as despu&eacute;s de  un IAM, comparado con placebo, con un seguimiento promedio de 42 meses.  La terapia con captopril se asoci&oacute; con un descenso de 19% de la mortalidad,  20% versus 25% placebo (IC 95%, 3%-32%); 37% de disminuci&oacute;n en la incidencia  de insuficiencia card&iacute;aca severa (IC 95%, 20%-50%); 22% de reducci&oacute;n de  la hospitalizaci&oacute;n por falla card&iacute;aca (IC 95%, 4%-37%), y 25% de reducci&oacute;n  de reinfarto (IC 95%, 5%-40%).&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> En el estudio TRACE (TRAndolapril Cardiaca Evaluation)<a name="-44"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#44">44</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2"> se incluyeron  1.749 pacientes entre el tercer y s&eacute;ptimo d&iacute;as pos IAM con FEVI &pound; 35% que  se aleatorizaron a trandolapril en dosis crecientes a 4 mg / d&iacute;a versus  placebo, con un seguimiento de dos a cuatro a&ntilde;os. Demostr&oacute; un descenso  de la mortalidad entre 25% y 30% (34,7% versus 42,3% para placebo), muerte  s&uacute;bita y progresi&oacute;n de la falla card&iacute;aca. A los seis a&ntilde;os de seguimiento,  los pacientes que recibieron trandolapril mejoraron la expectativa de vida  en 15,6 meses<a name="-45"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#45">45</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">; este beneficio persiste a los 12 a 19 a&ntilde;os; no existi&oacute;  reducci&oacute;n de reinfarto, a diferencia de lo acontecido con el estudio SAVE<a name="-46"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#46">46</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2"><font size="2">.&nbsp;</font> </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> <i>&nbsp; Pacientes con falla card&iacute;aca&nbsp;</i> </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> En el estudio cl&iacute;nico AIRE (Acute Infarction Ramipril Efficacy trial)</font><sup><font face="Verdana" size="2"><a name="-47"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#47">47</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">  se incluyeron 2.006 pacientes con falla card&iacute;aca pos IAM que se asignaron  a ramipril o placebo del tercer al d&eacute;cimo d&iacute;a pos IAM. Despu&eacute;s de un seguimiento  de 15 meses, el uso de ramipril se asoci&oacute; a 6% de descenso absoluto de  la mortalidad y una reducci&oacute;n significativa de la muerte s&uacute;bita de 30%,  con reducci&oacute;n en la progresi&oacute;n de la falla card&iacute;aca pero sin efecto en  el reinfarto o stroke</font><sup><font face="Verdana" size="2"><a name="-48"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#48">48</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">. El beneficio de la sobrevida por ramipril se  mantiene por largo tiempo<a name="-49"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#49">49</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2"><font size="2">.&nbsp;</font> </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> <i>&nbsp; Pacientes con IAM anterior&nbsp;</i> </font></p>        ]]></body>
<body><![CDATA[<p style="text-align: left;"><font face="Verdana" size="2"> <i>Sin reperfusi&oacute;n: </i>el estudio SMILE (Survival of Myocardial Infarction Long-tEm)  en 1.556 pacientes con IAM anterior, que no recibieron terapia de reperfusi&oacute;n,  randomiz&oacute; a zofenopril o placebo dentro de las primeras 24 horas a dosis  inicial de 7,5 mg y duplic&oacute; cada 12 horas hasta el objetivo de 30 mg dos  veces al d&iacute;a durante seis semanas. El zofenopril desciende significativamente  los puntos finales de muerte y falla card&iacute;aca severa a las seis semanas  en 7,1% versus 10,6%, y al a&ntilde;o en 10% versus 14%<a name="-50"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#50">50</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">. </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> <i>Posfibrin&oacute;lisis: </i>en pacientes que reciben fibrinol&iacute;ticos con IAM anterior  no se evidenci&oacute; beneficio; esta inconsistencia puede ser debida al peque&ntilde;o  n&uacute;mero de pacientes incluidos en estos estudios, como ejemplo, un metaan&aacute;lisis  de tres estudios que incluyeron a 845 pacientes no mostr&oacute; beneficio salvo  en la disminuci&oacute;n del volumen ventricular izquierdo, en quienes la reperfusi&oacute;n  fall&oacute;</font><sup><font face="Verdana" size="2"><a name="-51"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#51">51</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>         <p style="text-align: left;"><font face="Verdana" size="2"> <b>Momento de inicio.</b> Tanto la administraci&oacute;n temprana como tard&iacute;a tienen  beneficio. En 11 estudios en los cuales la administraci&oacute;n se realiz&oacute; dentro  de las primeras 48 horas, se comprob&oacute; una reducci&oacute;n significativa de la  mortalidad en el primer mes de 9,5% versus 10,1%.&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> En cuatro peque&ntilde;os estudios de administraci&oacute;n tard&iacute;a despu&eacute;s de las 48  horas se observ&oacute; una importante reducci&oacute;n de la mortalidad al a&ntilde;o: 14,3%  versus 16,5%.&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> El metaan&aacute;lisis de los estudios SAVE, AIRE, TRACE</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#43">43</a></font><font face="Verdana" size="2">,</font><font color="#1f1a17" face="Verdana" size="2"><a href="#44">44</a></font><font face="Verdana" size="2">,</font><font color="#1f1a17" face="Verdana" size="2"><a href="#47">47</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2"> de administraci&oacute;n  tard&iacute;a documentaron beneficio en la mortalidad a tres a&ntilde;os de 23,4% versus  29% (OR 0,74). Para salvar una vida tienen que ser tratados 15 pacientes  durante 30 meses (NNT), con reducci&oacute;n de las hospitalizaciones por falla  card&iacute;aca, 12% versus 15,5% (OR 0,73); sin diferencias en el riesgo de stroke.  El beneficio del tratamiento aparece r&aacute;pidamente, a las seis semanas de  iniciado redujo la mortalidad: 6% versus 7,9%.&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> <b>&iquest;Existen diferencias de f&aacute;rmacos? </b>Durante mucho tiempo se consider&oacute; que  el beneficio era debido a un efecto de clase; sin embargo, no est&aacute; establecido  si todos los I-ECA tienen un efecto equivalente en la sobrevida despu&eacute;s  de un IAM.&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> Un estudio retrospectivo de cohorte efectuado en 109 hospitales de Quebec,  Canad&aacute;, que incluy&oacute; a 7.512 pacientes de 65 a&ntilde;os o m&aacute;s con IAM, en quienes  se prescribi&oacute; un I-ECA dentro de los 30 d&iacute;as posteriores al mismo<a name="-52"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#52">52</a></font><font face="Verdana" size="2">) </font> </sup> <font face="Verdana" size="2">y  que continuaron recibiendo el f&aacute;rmaco durante un a&ntilde;o, evidenci&oacute; que la  mortalidad fue significativamente m&aacute;s baja para el grupo que recib&iacute;a ramipril  y perindopril que para los tratados con enalapril, lisinopril, captopril,  fosinopril o quinapril. Deben considerarse las conclusiones con cierta  limitaci&oacute;n, ya que exist&iacute;an diferencias basales entre las poblaciones</font><sup><font face="Verdana" size="2"><a name="-53"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#53">53</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>        <p style="text-align: left;"><font face="Verdana" size="2"> <b>Contraindicaciones. </b>Las contraindicaciones para el uso de los I-ECA son:&nbsp; </font></p>    <ul style="text-align: left;">                        <ul>             <li><font face="Verdana" size="2">     hipotensi&oacute;n arterial con presi&oacute;n arterial sist&oacute;lica &lt; de 90 mm Hg o &lt; de   30 mm Hg, respecto de la basal, que determine una inadecuada precarga; </font>   </li>                            </ul>                   <ul>               ]]></body>
<body><![CDATA[<li><font face="Verdana" size="2">shock;&nbsp;       </font></li>               <li><font face="Verdana" size="2"> historia de estenosis bilateral de las arterias renales;&nbsp;       </font></li>               <li><font face="Verdana" size="2"> antecedente de disminuci&oacute;n de la funci&oacute;n renal con I-ECA;&nbsp;       </font></li>               <li><font face="Verdana" size="2"> hipersensibilidad conocida al f&aacute;rmaco;&nbsp;       </font></li>               <li><font face="Verdana" size="2"> embarazo. </li>              <br>                            </font>                            </ul>                 </ul>    <font face="Verdana" size="2">   <b>Bloqueadores de los receptores de angiotensina II&nbsp;</b> </font> <ul>                                    <p style="text-align: left;"><font face="Verdana" size="2">Al igual que los I-ECA, los ARA II reducen la estimulaci&oacute;n de los receptores  de angiotensina II pero por un mecanismo diferente. Dos estudios cl&iacute;nicos  compararon su efecto con los I-ECA, como el VALIANT, que compar&oacute; valsart&aacute;n  con captopril, y el OPTIMAAL, que compar&oacute; losart&aacute;n con captopril; en ambos  trabajos no se demostr&oacute; superioridad de los ARA II sobre los I-ECA. En  el estudio OPTIMAAL, el valsart&aacute;n a la dosis de 160 mg dos veces por d&iacute;a  parece ser tan efectivo como el captopril en reducir la mortalidad<a name="-54"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#54">54</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp;</font></p>                   <p style="text-align: left;"><font face="Verdana" size="2">No se encontr&oacute; beneficio de la asociaci&oacute;n de ARA II con I-ECA en comparaci&oacute;n  con la monoterapia.&nbsp;   </font></p>                            ]]></body>
<body><![CDATA[<p style="text-align: left;"><font face="Verdana" size="2">   <b>En suma&nbsp;</b>   </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2"> El efecto beneficioso de los IECA/ARA II sobre la sobrevida es aditivo  al obtenido con otras medicaciones como aspirina, BB y estatinas, y se  observa en pacientes con SCA con y sin elevaci&oacute;n del segmento ST, tanto  con el uso temprano como tard&iacute;o. De todas formas existe importante evidencia  de que deben administrarse lo antes posible.&nbsp;   </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2"> Las gu&iacute;as actuales de tratamiento de los SCA con y sin elevaci&oacute;n del segmento  ST realizan las siguientes recomendaciones con respecto a la inhibici&oacute;n  del SRAA</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#4">4-7</a></font></sup><font face="Verdana" size="2"><sup>)</sup>. </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2"> Se debe iniciar un I-ECA en las primeras 24 horas a todos los pacientes  con SCAcST de localizaci&oacute;n anterior, falla card&iacute;aca o FEVI &pound; 40%, salvo  que existan contraindicaciones (Indicaci&oacute;n IA).&nbsp;   </font></p>                                    <p style="text-align: left;"><font face="Verdana" size="2"> En los pacientes con SCAsST con falla card&iacute;aca, FEVI &pound; 40%, hipertensi&oacute;n  o diabetes, se debe indicar y mantener por forma indefinida un I-ECA (Indicaci&oacute;n  I A).&nbsp;    <br>      </font></p>                   <p style="text-align: left;"><font face="Verdana" size="2">Se sugiere iniciar I-ECA en todos los pacientes con SCAcST y SCAsST que  no presenten contraindicaciones (Indicaci&oacute;n II A).&nbsp;   </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2"> En los pacientes que no toleren el uso de I-ECA y presenten SCAcST, se  debe administrar un ARA II (Indicaci&oacute;n I B) al igual que en aquellos pacientes  con SCAsST (Indicaci&oacute;n I A).&nbsp;   </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2"> Se sugiere continuar con esta terapia indefinidamente (Indicaci&oacute;n II B).&nbsp;   </font></p>             </ul>        ]]></body>
<body><![CDATA[<div style="text-align: left;"><font face="Verdana" size="2">    <br>      </font>    </div>        <div style="text-align: left;"><font face="Verdana" size="2">   <b>Antagonistas de los receptores mineralocorticodes. Espironolactona y eplerenona&nbsp;</b></font></div>    <ul>                            <p style="text-align: left;"><font face="Verdana" size="2"> Los I-ECA/ARA II y los BB no inhiben uniformemente el SRAA. El producto  final, la aldosterona, aumenta en los tratamientos prolongados hasta 40%  o m&aacute;s, lo que se observ&oacute; durante tratamientos de insuficiencia card&iacute;aca.  Esta situaci&oacute;n cl&iacute;nica promueve retenci&oacute;n de sodio, injuria cardiovascular  y renal.&nbsp;   </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2"> El fen&oacute;meno del escape de aldosterona provee una explicaci&oacute;n a la disminuci&oacute;n  de la mortalidad cuando se usa espironolactona en combinaci&oacute;n con I-ECA  en pacientes con falla card&iacute;aca avanzada (estudio RALES)<a name="-55"></a></font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#55">55</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2"> El estudio EPHESUS</font><sup><font face="Verdana" size="2"><a name="-56"></a><a name="-57"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#56">56-57</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2"> (Eplerenona Post- Acute Myocardial Infarction  Heart Failure Efficacy and Survival Study) aleatoriz&oacute; a 6.642 pacientes  con SCAcST con FEVI &lt; 40%, e insuficiencia card&iacute;aca o diabetes, en tratamiento  habitual con BB e I-ECA/ARAII, al uso de eplerenone o placebo. El seguimiento  a 16 meses demostr&oacute; beneficio con reducci&oacute;n significativa de la muerte  cardiovascular, muerte s&uacute;bita y hospitalizaci&oacute;n por falla card&iacute;aca.&nbsp; </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2"> Este efecto est&aacute; presente a los 30 d&iacute;as y ocurre solo cuando se administra  el f&aacute;rmaco entre los tres a siete d&iacute;as pos IAM.&nbsp;   </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2"> En comparaci&oacute;n con la espironolactona, la eplerenona tiene mayor afinidad  con los receptores mineralocorticoides y, por tanto, mayor inhibici&oacute;n del  efecto de la aldosterona, lo que es independiente de su acci&oacute;n diur&eacute;tica  y ahorradora de potasio.&nbsp;   </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2"> La reducci&oacute;n de la mortalidad del primer mes se deber&iacute;a a la reducci&oacute;n  de la muerte s&uacute;bita y del remodelado ventricular. La atenuaci&oacute;n de este  beneficio en los sobrevivientes al primer mes puede deberse a un <i>feedback  </i>positivo por mecanismo neurohormonal mal adaptativo.&nbsp;   </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2"> Futuros estudios que permitan reconocer el incompleto antagonismo neurohormonal  permitir&aacute;n la optimizaci&oacute;n de las dosis administradas.&nbsp;   </font></p>                            ]]></body>
<body><![CDATA[<p style="text-align: left;"><font face="Verdana" size="2"> El ACCF, la AHA y la European Society of Cardiology recomiendan: 1) Antes  de iniciar el tratamiento, verificar que los niveles de potasio y de creatinina  plasm&aacute;ticos sean inferiores a 5 mmol/l y 2,5 mg/dl, respectivamente. 2)  Medir la funci&oacute;n renal a trav&eacute;s de la creatinina plasm&aacute;tica y del clearance  de creatinina. 3) Suspender o reducir los suplementos de potasio. 4) La  dosis de inicio de eplerenona es de 25 mg/d&iacute;a y la de espironolactona de  12,5 a 25 mg/d&iacute;a. 5) Luego de comenzar el tratamiento, los valores plasm&aacute;ticos  de potasio y la funci&oacute;n renal se deben controlar en los tres primeros d&iacute;as  y a la semana (se sugiere proceder de manera similar con cada cambio de  dosis). Durante los primeros tres meses de tratamiento, el control de los  niveles de potasio y la funci&oacute;n renal debe ser mensual. 6) Si el nivel  de potasio es superior a 5,5 mmol/l, se debe reducir a la mitad la dosis  de los f&aacute;rmacos. Si las dosis eran las menores recomendadas, indicar un  esquema d&iacute;a por medio. Si el nivel de potasio supera los 6 mmol/l, suspender  el tratamiento y reiniciarlo cuando los valores sean inferiores. 7) Si  despu&eacute;s de un mes de tratamiento los niveles de potasio son normales, se  debe incrementar la dosis a 50 mg/d&iacute;a. 8) Evitar la administraci&oacute;n de antiinflamatorios  no esteroideos y de inhibidores de la ciclooxigenasa tipo 2. Si se deben  emplear, controlar dentro de la semana de iniciados los niveles de potasio  y la funci&oacute;n renal. 9) Suspender el tratamiento con bloqueantes de la aldosterona  en caso de v&oacute;mitos o diarrea y tener en cuenta otras causas posibles de  deshidrataci&oacute;n, como el incremento de la dosis de diur&eacute;ticos</font><sup><font face="Verdana" size="2"><a name="-58"></a>(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#58">58</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>                             <p style="text-align: left;">       <multicol gutter="18" cols="2"></multicol>   </p>                           <p style="text-align: left;"><font face="Verdana" size="2"> Los expertos concluyen que en los pacientes con insuficiencia card&iacute;aca  pos IAM, el tratamiento con f&aacute;rmacos que bloquean la actividad de la aldosterona  se asocia con reducci&oacute;n de la morbi-mortalidad. Dado que en esta poblaci&oacute;n  la mortalidad temprana es elevada, recomiendan iniciar dicho tratamiento  tan pronto como las condiciones hemodin&aacute;micas lo permitan</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#58">58</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp; </font></p>                            <p style="text-align: left;"><font face="Verdana" size="2">   <b>En suma&nbsp;</b>   </font></p>                 </ul>        <div style="text-align: left;"><font face="Verdana" size="2"> En los pacientes con SCAcST con FEVI &lt; 40% y falla card&iacute;aca o diabetes  se debe iniciar un antagonista de la aldosterona si no existen contraindicaciones  para su uso (Indicaci&oacute;n I B)</font><sup><font face="Verdana" size="2">(</font><font color="#1f1a17" face="Verdana" size="2"><a href="#4">4-5</a></font><font face="Verdana" size="2">)</font></sup><font face="Verdana" size="2">.&nbsp;</font></div>    <ul>                   <p align="left">&nbsp;</p>                                <p align="left"><font face="Verdana" size="2">   <b>Bibliograf&iacute;a&nbsp;</b>   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="1"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-1">1</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Raju TN. </b>The Nobel cronicles. 1988: James Whyte Black, (b 1924), Gertrude  Elion (1918-99), and George H Hitchings (1905-98). Lancet 2000; 335(9208):  1022.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330766&pid=S1688-0420201400010001400001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font face="Verdana" size="2"><a name="2"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-2">2</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Waagstein F, Hjalmarson A, Wasir HS.</b> Apex cardiogram and systolic intervals  in acute myocadial infarction and effect of practolol. Br Heart J 1974;  36:1109-21.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330768&pid=S1688-0420201400010001400002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="3"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-3">3</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. </b>Prolongation of survival  in congestive cardiyopathy by betareceptor blockade. Lancet 1979; 1(8131):1374-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330770&pid=S1688-0420201400010001400003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <p align="left"><font face="Verdana" size="2"><a name="4"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-4">4</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>O&rsquo;Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA,  et al.</b> 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial  Infarction: Executive Summary : A Report of the American College of Cardiology  Foundation/American Heart Association Task Force on Practice Guidelines.  Circulation 2013; 127(4):529-555&nbsp;   </font></p>                            <p align="left"><font face="Verdana" size="2"><a name="5"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-5">5</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Steg PG, James SK, Atar D, Badano LP, Bl&ouml;mstrom-Lundqvist C, Borger MA,  et al.</b> ESC Guidelines for the management of acute myocardial infarction  in patients presenting with ST-segment elevation. The Task Force on the  management of ST-segment elevation acute myocardial infarction of the European  Society of Cardiology (ESC). Eur Heart J 2012; 33(2): 2569&ndash;2619&nbsp;   </font></p>                            <p align="left"><font face="Verdana" size="2"><a name="6"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-6">6</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al.</b> 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007  Guidelines for the Management of Patients With Unstable Angina/Non&ndash;ST-Elevation  Myocardial Infarction. A Report of the American College of Cardiology Foundation/American  Heart Association Task Force on Practice Guidelines. Circulation 2013;  127(23):e663-e828.&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="7"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-7">7</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. </b>ESC  Guidelines for the management of acute coronary syndromes in patients presenting  without persistent ST-segment elevation. The Task Force for the management  of acute coronary syndromes (ACS) in patients presenting without persistent  ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart  J 2011; 32(23):2999-3054 doi:10.1093/eurheartj/ ehr236.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330775&pid=S1688-0420201400010001400007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="8"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-8">8</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>L&oacute;pez-Send&oacute;n J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie  H, et al.</b> Expert consensus document on beta-adrenergic receptor blockers.  Eur Heart J 2004; 25(15):1341-62.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330777&pid=S1688-0420201400010001400008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="9"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-9">9</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Ryd&eacute;n L, Ariniego R, Arnman K, Herlitz J, Hjalmarson A, Holmberg S, et al.</b> A double-blind trial of metoprolol in acute myocardial infarction.  Effects on ventriculae tachyarrthythmias. N Engl J Med 1983; 308(11): 614-18.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330779&pid=S1688-0420201400010001400009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="10"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-10">10</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Nuttall SL, Toescu V, Kendall MJ. </b>Beta blockade after myocardial infarction.  Beta blockers have key role in reducing morbidity and mortality after myocardial  infarction. BMJ 2000; 320(7234): 581.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330781&pid=S1688-0420201400010001400010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="11"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-11">11</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Friedman LM, Byington RP, Capone RJ, Furberg CD, Goldstein S, Lichstein  E.</b> Effect of propanolol in patients with myocardial infarction and ventricular  arrhythmia. J Am Coll Cardiol 1986; 7(1): 1-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330783&pid=S1688-0420201400010001400011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="12"></a>    </font><font color="#1f1a17" face="Verdana" size="2"> <a href="#-12">12</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Hu K, Gaudron P, Ertl G. </b>Long-term effects of beta-adrenergic blocking  agent treatment on hemodynamic function and left ventricular remodeling  in rats with experimental myocardial infarction: importance of timing of  treatment and infarct size. J Am Coll Cardiol 1998; 31(3): 692-700.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330785&pid=S1688-0420201400010001400012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="13"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-13">13</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Galcer&aacute;-Tom&aacute;s J, Castillo-Soria FJ, Villegas-Garc&iacute;a MM, Florenciano-S&aacute;nchez  R, S&aacute;nchez-Villanueva JG, de La Rosa JA, et al.</b> Effects of early use of  atenolol or captopril on infarct size and ventricular volumen: A double-blind  comparison in patients with anterior acute myocardial infarction. Circulation  2001; 103(6): 813-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330787&pid=S1688-0420201400010001400013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>           <multicol gutter="18" cols="2"></multicol>                      <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="14"></a>    </font><font color="#1f1a17" face="Verdana" size="2"> <a href="#-14">14</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Doughty RN, Whalley GA, Walsh HA, Gamble GD, L&oacute;pez-Send&oacute;n J, Sharpe  N. </b>Effects of carvedilol on left ventricular remodeling after acute myocardial:  the CAPRICORN Echo Substudy. Circulation 2004; 109(2): 201-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330789&pid=S1688-0420201400010001400014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="15"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-15">15</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Poulsen SH, Jensen SE, Egstrup K.</b> Effects of long-term adrenergic beta-blockade  on left ventricular diastolic filling in patients with acute myocardial  infarction. Am Heart J 1999; 138(4 Pt 1):710-20.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330791&pid=S1688-0420201400010001400015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="16"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-16">16</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Sipahi I, Tuzcu EM, Wolski KE, Nicholls SJ, Schoenhagen P, Hu B, et al.</b> Beta-blockers and progression of coronary atherosclerosis: pooled analysis  of 4 intravascular ultravascular ultrasonography trials. Ann Intern Med  2007; 147(1): 10-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330793&pid=S1688-0420201400010001400016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="17"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-17">17</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Yusuf S, Peto R, Lewis J, Collins R, Sleight P.</b> Beta blockade during  and after myocardial infarction: an overview of the randomized trials.  Prog cardiovascular Dis 1985; 27(5): 335-71.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330795&pid=S1688-0420201400010001400017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="18"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-18">18</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;Timolol-induced reduction in mortality and reinfarction in patients  surviving acute myocardial infarction. N Engl J Med 1981; 304(14): 801-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330797&pid=S1688-0420201400010001400018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="19"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-19">19</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Hjalmarson A, Herlitz J, Holmberg S, Ryd&eacute;n L, Swedberg K, Vedin A, et al. </b>The G&ouml;teborg metoprolol trial. Effect on mortality and morbilidity  in acute myocardial infarction. Circulation 1983; 67(6pt2):126-32.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330799&pid=S1688-0420201400010001400019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="20"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-20">20</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Chadda K, Goldstein S, Byington R, Curb JD.</b> Effect of propranolol after  acute myocardial infarction in patients with congestive heart failure.  Circulation 1986; 73(3): 503-10.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330801&pid=S1688-0420201400010001400020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="21"></a>   </font><font color="#1f1a17" face="Verdana" size="2"><a href="#-21"> 21</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Metoprolol in acute myocardial infarction (MIAMI).</b> A randomized placebo-controlled  international trial. The MIAMI Trial Research Group. Eur Heart J 1985;  6(3): 199-226.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330803&pid=S1688-0420201400010001400021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="22"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-22">22</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;Randomised trail of intravenous atenolol among 16027 cases of suspected  acute myocardial infarction: ISIS-1. First Internacional Study of infarct  Survival Collaborative Group. Lancet 1986; 2(8498): 57-66.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330805&pid=S1688-0420201400010001400022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="23"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-23">23</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, et al. </b>Immediate versus deferred beta-blockade following thrombolytic therapy  in patients with acute myocardial infarction. Results of the Thrombolysis  in Myocardial Infarction (TIMI) II-B Study. Circulation 1991; 83(2):422-37.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330807&pid=S1688-0420201400010001400023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="24"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-24">24</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Freemantie N, Cleland J, Young P, Mason J, Harrison J. </b>Netab Blockade  after myocardial systematic review and meta regression analysis. BMJ 1999;  318 (7200):1730-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330809&pid=S1688-0420201400010001400024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="25"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-25">25</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Silvet H, Spencer F, Yarzebski J, Lessard D, Gore JM, Goldberg RJ. </b>Community  wide trends in the use and outcomes associated with beta-blockers in patients  with acute myocardial infarction: the Worcester Heart Attack Study. Arch  Intern Med 2003; 163(18):2175-83.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330811&pid=S1688-0420201400010001400025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="26"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-26">26</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW,  et al. </b>Acute coronary care in the elderly, part II: ST-segment-elevation  myocardial : a scientific statement for healthcare professionals from the  American Heart Association Council on Clinical Cardiology: in collaboration  with the Society of Geriatric Cardiology. Circulation 2007; 115(19):2570-89.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330813&pid=S1688-0420201400010001400026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="27"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-27">27</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. </b>Early intravenous then oral metoprolol in 45,852 patients with acute  myocardial infarction: randomised placebo-controlled trial. Lancet 2005;  366:1622-32.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330815&pid=S1688-0420201400010001400027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <p align="left"><font face="Verdana" size="2"><a name="28"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-28">28</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Dargie HJ. </b>Effect of carvedilol on out come after myocardial infarction  in patients with left &ndash;ventricular dysfunction: the CAPRICORN randomized  trail. Lancet 2001; 357(9266):1385-90.&nbsp;   </font></p>                            ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font face="Verdana" size="2"><a name="29"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-29">29</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Nuttall SL, Toescu V, Kendall MJ.</b> Beta blockade after myocardial infarction.  Beta blockers have key role in reducing morbidity and mortality after infarction.  BMJ 2000; 320(7234):581.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330818&pid=S1688-0420201400010001400029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="30"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-30">30</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Friedman LM, Byington RP, Capone RJ, Furberg CD, Goldstein S, Lichstein  E. </b>Effect of propranolol in patients with myocardial infarction and ventricular  arrhythmia. J Am Coll Cardiol 1986; 7(1):1-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330820&pid=S1688-0420201400010001400030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <p align="left"><font face="Verdana" size="2"><a name="31"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-31">31</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Feit F, Mueller HS, Braunwald E, Ross R, Hodges M, Herman MV, et al.</b>  Thrombolysis in Myocardial Infarction (TIMI) phase II trial: outcome comparison  of a &ldquo;conservative strategy&rdquo; in community versus tertiary hospitals. The  TIMI Research Group. J Am Coll Cardiol 1990 Dec; 16(7):1529-34.&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="32"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-32">32</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, et al.</b>  A prospective survey of characteristics, treatments and outcomes of patients  with acute coronary syndromes in Europe and the Mediterranean basin; the  Euro Heart Srvey of Acute Coronary Syndromes (Euro Heart Survey ACS) Eur  Heart J 2002; 23(15):1190-201.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330823&pid=S1688-0420201400010001400032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="33"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-33">33</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Flather MD, et al. </b>Baseline characteristics management practices and in-hospital outcomes  of patients hospitalized with acute coronary syndromes in the Global Registry  of Acute Coronary Events (GRACE). Am J Cardiol 2002; 90(4):358-63.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330825&pid=S1688-0420201400010001400033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="34"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-34">34</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Cucherat M. </b>Quantitative relationship between resting heart rate reduction  and magnitude of clinical benefits in post-myocardial infarction: a meta-regression  of randomized clinical trials. Eur Heart J 2007; 28(24):3012-19.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330827&pid=S1688-0420201400010001400034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                             <p>    <multicol gutter="18" cols="2"></multicol>   </p>                           <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="35"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-35">35</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Korup E, Dalsgaard D, Nyvad O, Jensen TM, Toft E, Berning J. </b>Comparison  of degrees of left ventricular dilation within three hours and up to six  days after onset of first acute myocardial infarction. Am J Cardiol 1997;  80(4):449-53.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330830&pid=S1688-0420201400010001400035&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="36"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-36">36</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Hutchins GM, Bulkley BH. </b>Infarct expansion versus extension: two different  complications of acute myocardial infarction. Am J Cardiol 1978; 41(7):1127-32.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330832&pid=S1688-0420201400010001400036&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="37"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-37">37</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Miki T, Miura T, Tsuchida A, Nakano A, Hasegawa T, Fukuma T, et al.</b>  Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct  ventricular remodeling through angiotensin II type 1 receptor activation.  Circulation 2000; 102(4):458-63.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330834&pid=S1688-0420201400010001400037&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="38"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-38">38</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. </b>Effect of angiotensin converting enzyme inhibition on sudden cardiac death  in patients following acute myocardial infarction. A meta-analysis of randomized  clinical trials. J Am Coll Cardiol 1999; 33(3):598-604.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330836&pid=S1688-0420201400010001400038&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            ]]></body>
<body><![CDATA[<!-- ref --><p align="left"><font face="Verdana" size="2"><a name="39"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-39">39</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Ambrosioni E, Borghi C, Magnani B. </b>The effect of the angiotensin-converting-enzyme  inhibitor zofenopril on mortality and morbidity after anterior myocardial  infarction. The Survival of Myocardial Infarction Long-Term Evaluation  (SMILE) Study Investigators. N Engl J Med 1995; 332(2):80-85.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330838&pid=S1688-0420201400010001400039&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <p align="left"><font face="Verdana" size="2"><a name="40"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-40">40</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Fourth International Study of Infarct Survival) Collaborative Group ISIS-4.</b> IiSIS-4: A randomised factorial trial assessing early oral captopril,  oral mononitrate, and intravenous magnesium sulphate in 58 050 patients  with suspected acute myocardial infarction. Lancet 1995; 345(8951):669&ndash;82.&nbsp;   </font></p>                            <p align="left"><font face="Verdana" size="2"><a name="41"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-41">41</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Gruppo Italiano per lo Studio della Sopravvivenza nell&rsquo;infarto Miocardico. </b>GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly  and together on 6-week mortality and ventricular function after acute myocardial  infarction. Lancet 1994; 343(8906):1115-22.&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="42"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-42">42</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. </b>Effect of the ACE inhibitor lisinopril on mortality in diabetic patients  with acute myocardial infarction: data from the GISSI-3 study. Circulation  1997; 96(12):4239-45.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330842&pid=S1688-0420201400010001400042&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="43"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-43">43</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Rutherford JD, Pfeffer MA, Moy&eacute; LA, Davis BR, Flaker GC, Kowey PR, et al. </b>Effects of captopril on ischemic events after myocardial infarction.  Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.  Circulation 1994; 90(4):1731-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330844&pid=S1688-0420201400010001400043&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <p align="left"><font face="Verdana" size="2"><a name="44"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-44">44</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>K&oslash;ber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg  K, et al.</b> The A Clinical Trial of the Angiotensin-Converting&ndash;Enzyme Inhibitor  Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial  Infarction. Trandolapril Cardiac Evaluation (TRACE) study group. N Engl  J Med 1995; 333:1670-76.&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="45"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-45">45</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Torp-Pedersen C, K&oslash;ber L. </b>Effect of ACE inhibitor trandolapril on life  expectancy of patients with reduced left-ventricular function after acute  myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation.  Lancet 1999; 354(9172):9-12.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330847&pid=S1688-0420201400010001400045&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="46"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-46">46</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Buch P, Rasmussen S, Abildstrom SZ, K&oslash;ber L, Carlsen J, Torp-Pedersen  C. </b>The long-term impact of the angiotensin-converting enzyme inhibitor  trandolapril on mortality and hospital admissions in patients with left  ventricular dysfunction after a myocardial infarction: follow-up to 12  years. Eur Heart J 2005; 26(2):145-52.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330849&pid=S1688-0420201400010001400046&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="47"></a>   </font><font color="#1f1a17" face="Verdana" size="2"><a href="#-47">47</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.</b> Effect  of ramipril on mortality and morbidity of survivors of acute myocardial  infarction with clinical evidence of heart failure. Lancet 1993; 342(8875):821-28.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330851&pid=S1688-0420201400010001400047&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="48"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-48">48</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. </b>Effect of ramipril  on morbidity and mode of death among survivors of acute myocardial infarction  with clinical evidence of heart failure. A report from the AIRE Study Investigators.  Eur Heart J 1997; 18(1):41-51.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330853&pid=S1688-0420201400010001400048&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="49"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-49">49</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Hall AS, Murray GD, Ball SG.</b> Follow-up study of patients randomly allocated  ramipril or placebo for heart failure after acute myocardial infarction:  AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet  1997; 349 (9064):1493-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330855&pid=S1688-0420201400010001400049&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="50"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-50">50</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Ambrosioni E, Borghi C, Magnani B.</b> The SMILE study: the rationale, design,  organization and definition of the objectives. Survival of Myocardial Infarction  Long-term Evaluation. Ann Ital Med Int 1993 Oct-Dec; 8(4):230-4.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330857&pid=S1688-0420201400010001400050&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="51"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-51">51</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>de Kam PJ, Voors AA, van den Berg MP, van Veldhuisen DJ, Brouwer J,  Crijns HJ, et al. </b>Effect of very early angiotensin-converting enzyme inhibition  on left ventricular dilation after myocardial infarction in patients receiving  thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN  and CATS Investigators. J Am Coll Cardiol 2000; 36(7):2047-53.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330859&pid=S1688-0420201400010001400051&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="52"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-52">52</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E. </b>Mortality  rates in elderly patients who take different angiotensin-converting enzyme  inhibitors after acute myocardial infarction: a class effect? Ann Intern  Med 2004; 141(2):102-12.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330861&pid=S1688-0420201400010001400052&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="53"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-53">53</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Hennessy S, Kimmel SE.</b> Is improved survival a class effect of angiotensin-converting  enzyme inhibitors? Ann Intern Med 2004; 141(2):157-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330863&pid=S1688-0420201400010001400053&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="54"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-54">54</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group.</b> Effects of losartan and captopril on mortality and morbidity  in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised  trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist  Losartan. Lancet 2002 Sep 7; 360(9335):752-60.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330865&pid=S1688-0420201400010001400054&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>           <multicol gutter="18" cols="2"></multicol>                      <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="55"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-55">55</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. </b>The  effect of spironolactone on morbidity and mortality in patients with severe  heart failure. N Engl J Med 1999; 341(10):709-17.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330867&pid=S1688-0420201400010001400055&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="56"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-56">56</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, et al.</b> EPHESUS trial: eplerenone in patients with heart failure due to systolic  dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI  Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001Jan;  15 (1):79-87.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330869&pid=S1688-0420201400010001400056&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="57"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-57">57</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al.</b> Eplerenone,  a selective aldosterone blocker in patients with left ventricular dysfunction  after myocardial infarction. N Engl J Med 2003; 348(14):1309-21.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330871&pid=S1688-0420201400010001400057&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                            <!-- ref --><p align="left"><font face="Verdana" size="2"><a name="58"></a>   </font><font color="#1f1a17" face="Verdana" size="2">   <a href="#-58">58</a></font><font face="Verdana" size="2">.&nbsp;&nbsp;&nbsp;&nbsp;<b>Pitt B, Ferrari R, Gheroghiade M, van Veldhuisen DJ, Krum H, McMurray  J, et al.</b> Aldosterone Blockade in Post-Acute Myocardial Infarction Heart  Failure. Clin Cardiol 2006; 29(10):434-38.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=330873&pid=S1688-0420201400010001400058&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->&nbsp;   </font></p>                             <p>    </p>          </ul>           ]]></body>
<back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raju]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Nobel cronicles: 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2000</year>
<volume>335</volume>
<numero>9208</numero>
<issue>9208</issue>
<page-range>1022</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waagstein]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hjalmarson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wasir]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Apex cardiogram and systolic intervals in acute myocadial infarction and effect of practolol]]></article-title>
<source><![CDATA[Br Heart J]]></source>
<year>1974</year>
<volume>36</volume>
<page-range>1109-21</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swedberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hjalmarson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Waagstein]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wallentin]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prolongation of survival in congestive cardiyopathy by betareceptor blockade]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1979</year>
<volume>1</volume>
<numero>8131</numero>
<issue>8131</issue>
<page-range>1374-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&rsquo;Gara]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Kushner]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
<name>
<surname><![CDATA[Ascheim]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[DE Jr]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[de Lemos]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2013</year>
<volume>127</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>529-555</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Atar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Badano]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Blömstrom-Lundqvist]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Borger]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2012</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>2569-2619</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Antman]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Bridges]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Califf]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[DE Jr]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2013</year>
<volume>127</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>e663-e828</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamm]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Bassand]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Agewall]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bax]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boersma]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bueno]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2011</year>
<volume>32</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2999-3054</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Sendón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Swedberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tamargo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Maggioni]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Dargie]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Expert consensus document on beta-adrenergic receptor blockers]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2004</year>
<volume>25</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1341-62</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rydén]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ariniego]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Arnman]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Herlitz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hjalmarson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Holmberg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A double-blind trial of metoprolol in acute myocardial infarction: Effects on ventriculae tachyarrthythmias]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1983</year>
<volume>308</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>614-18</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nuttall]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Toescu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kendall]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Beta blockade after myocardial infarction: Beta blockers have key role in reducing morbidity and mortality after myocardial infarction]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2000</year>
<volume>320</volume>
<numero>7234</numero>
<issue>7234</issue>
<page-range>581</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Byington]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Capone]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Furberg]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lichstein]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of propanolol in patients with myocardial infarction and ventricular arrhythmia]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1986</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gaudron]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ertl]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Long-term effects of beta-adrenergic blocking agent treatment on hemodynamic function and left ventricular remodeling in rats with experimental myocardial infarction: importance of timing of treatment and infarct size]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1998</year>
<volume>31</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>692-700</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galcerá-Tomás]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo-Soria]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Villegas-García]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Florenciano-Sánchez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Villanueva]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[de La Rosa]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of early use of atenolol or captopril on infarct size and ventricular volumen: A double-blind comparison in patients with anterior acute myocardial infarction]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2001</year>
<volume>103</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>813-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doughty]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Whalley]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Gamble]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[López-Sendón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sharpe]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of carvedilol on left ventricular remodeling after acute myocardial: the CAPRICORN Echo Substudy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2004</year>
<volume>109</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>201-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poulsen]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Egstrup]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of long-term adrenergic beta-blockade on left ventricular diastolic filling in patients with acute myocardial infarction]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>1999</year>
<volume>138</volume>
<numero>4 Pt 1</numero>
<issue>4 Pt 1</issue>
<page-range>710-20</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sipahi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tuzcu]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Wolski]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Nicholls]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schoenhagen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultravascular ultrasonography trials]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2007</year>
<volume>147</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Peto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sleight]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Beta blockade during and after myocardial infarction: an overview of the randomized trials]]></article-title>
<source><![CDATA[Prog cardiovascular Dis]]></source>
<year>1985</year>
<volume>27</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>335-71</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<article-title xml:lang="en"><![CDATA[Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1981</year>
<volume>304</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>801-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hjalmarson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Herlitz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Holmberg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rydén]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Swedberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vedin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Göteborg metoprolol trial: Effect on mortality and morbilidity in acute myocardial infarction]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1983</year>
<volume>67</volume>
<numero>6pt2</numero>
<issue>6pt2</issue>
<page-range>126-32</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chadda]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Byington]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Curb]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of propranolol after acute myocardial infarction in patients with congestive heart failure]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1986</year>
<volume>73</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>503-10</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<collab>The MIAMI Trial Research Group</collab>
<article-title xml:lang="en"><![CDATA[Metoprolol in acute myocardial infarction (MIAMI): A randomized placebo-controlled international trial]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>1985</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>199-226</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<collab>First Internacional Study of infarct Survival Collaborative Group</collab>
<article-title xml:lang="en"><![CDATA[Randomised trail of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1986</year>
<volume>2</volume>
<numero>8498</numero>
<issue>8498</issue>
<page-range>57-66</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Lambrew]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Diver]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1991</year>
<volume>83</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>422-37</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freemantie]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Netab Blockade after myocardial systematic review and meta regression analysis]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1999</year>
<volume>318</volume>
<numero>7200</numero>
<issue>7200</issue>
<page-range>1730-7</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silvet]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Spencer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Yarzebski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lessard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gore]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Community wide trends in the use and outcomes associated with beta-blockers in patients with acute myocardial infarction: the Worcester Heart Attack Study]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2003</year>
<volume>163</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>2175-83</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Newby]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Gibler]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Rich]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Acute coronary care in the elderly, part II: ST-segment-elevation myocardial : a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>115</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2570-89</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
<name>
<surname><![CDATA[Peto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[LX]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>366</volume>
<page-range>1622-32</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dargie]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of carvedilol on out come after myocardial infarction in patients with left -ventricular dysfunction: the CAPRICORN randomized trail]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2001</year>
<volume>357</volume>
<numero>9266</numero>
<issue>9266</issue>
<page-range>1385-90</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nuttall]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Toescu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kendall]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Beta blockade after myocardial infarction: Beta blockers have key role in reducing morbidity and mortality after infarction]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2000</year>
<volume>320</volume>
<numero>7234</numero>
<issue>7234</issue>
<page-range>581</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Byington]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Capone]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Furberg]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lichstein]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1986</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feit]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hodges]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Herman]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Thrombolysis in Myocardial Infarction (TIMI) phase II trial: outcome comparison of a &ldquo;conservative strategy&rdquo; in community versus tertiary hospitals]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1990</year>
<month> D</month>
<day>ec</day>
<volume>16</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1529-34</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hasdai]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Behar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wallentin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Danchin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gitt]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Boersma]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A prospective survey of characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Srvey of Acute Coronary Syndromes (Euro Heart Survey ACS)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2002</year>
<volume>23</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1190-201</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gore]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Eagle]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Flather]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Baseline characteristics management practices and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2002</year>
<volume>90</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>358-63</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cucherat]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2007</year>
<volume>28</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>3012-19</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Korup]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dalsgaard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nyvad]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Toft]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Berning]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparison of degrees of left ventricular dilation within three hours and up to six days after onset of first acute myocardial infarction]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1997</year>
<volume>80</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>449-53</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hutchins]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Bulkley]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Infarct expansion versus extension: two different complications of acute myocardial infarction]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1978</year>
<volume>41</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1127-32</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Miura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tsuchida]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nakano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hasegawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fukuma]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2000</year>
<volume>102</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>458-63</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domanski]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Exner]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Borkowf]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Geller]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeffer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1999</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>598-604</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ambrosioni]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Borghi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Magnani]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction: The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1995</year>
<volume>332</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>80-85</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<collab>Fourth International Study of Infarct Survival) Collaborative Group ISIS-4</collab>
<article-title xml:lang="en"><![CDATA[IiSIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1995</year>
<volume>345</volume>
<numero>8951</numero>
<issue>8951</issue>
<page-range>669-82</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<collab>Gruppo Italiano per lo Studio della Sopravvivenza nell&rsquo;infarto Miocardico</collab>
<article-title xml:lang="en"><![CDATA[GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1994</year>
<volume>343</volume>
<numero>8906</numero>
<issue>8906</issue>
<page-range>1115-22</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuanetti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Latini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Maggioni]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Franzosi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Santoro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tognoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1997</year>
<volume>96</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>4239-45</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rutherford]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeffer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Moyé]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Flaker]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Kowey]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of captopril on ischemic events after myocardial infarction: Results of the Survival and Ventricular Enlargement trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1994</year>
<volume>90</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1731-8</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Køber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Torp-Pedersen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Carlsen]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Bagger]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Eliasen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lyngborg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The A Clinical Trial of the Angiotensin-Converting-Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1995</year>
<volume>333</volume>
<page-range>1670-76</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torp-Pedersen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Køber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>354</volume>
<numero>9172</numero>
<issue>9172</issue>
<page-range>9-12</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buch]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abildstrom]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Køber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Carlsen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Torp-Pedersen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2005</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>145-52</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<collab>The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators</collab>
<article-title xml:lang="en"><![CDATA[Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1993</year>
<volume>342</volume>
<numero>8875</numero>
<issue>8875</issue>
<page-range>821-28</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Erhardt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Ball]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure: A report from the AIRE Study Investigators]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>1997</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-51</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Ball]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1997</year>
<volume>349</volume>
<numero>9064</numero>
<issue>9064</issue>
<page-range>1493-7</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ambrosioni]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Borghi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Magnani]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The SMILE study: the rationale, design, organization and definition of the objectives. Survival of Myocardial Infarction Long-term Evaluation]]></article-title>
<source><![CDATA[Ann Ital Med Int]]></source>
<year>1993</year>
<month> O</month>
<day>ct</day>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>230-4</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Kam]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Voors]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[van den Berg]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[van Veldhuisen]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brouwer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Crijns]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2000</year>
<volume>36</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2047-53</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pilote]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Abrahamowicz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Eisenberg]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rahme]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2004</year>
<volume>141</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>102-12</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hennessy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kimmel]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Is improved survival a class effect of angiotensin-converting enzyme inhibitors?]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2004</year>
<volume>141</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>157-8</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dickstein]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kjekshus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<month> S</month>
<day>ep</day>
<volume>360</volume>
<numero>9335</numero>
<issue>9335</issue>
<page-range>752-60</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Remme]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cody]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Castaigne]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The effect of spironolactone on morbidity and mortality in patients with severe heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>341</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>709-17</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Remme]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Sendon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study]]></article-title>
<source><![CDATA[Cardiovasc Drugs Ther]]></source>
<year>2001</year>
<month>Ja</month>
<day>n</day>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>79-87</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Remme]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Neaton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Roniker]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>348</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1309-21</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gheroghiade]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van Veldhuisen]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Krum]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Aldosterone Blockade in Post-Acute Myocardial Infarction Heart Failure]]></article-title>
<source><![CDATA[Clin Cardiol]]></source>
<year>2006</year>
<volume>29</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>434-38</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
